Search

A cardiac implantable electronic device (CIED) survey was undertaken in Australia and New Zealand for calendar year 2021. The survey involved pacemakers (PMs) and implantable cardioverter-defibrillators (ICDs). The survey was conducted on the 50For 2021, there were 19,410 PMs (17,971 in 2017) sold in Australia for new implants and 2,282 (1,811 in 2017) sold in New Zealand. The number of new PM implants per million population was 755 for Australia (745 in 2017) and 446 for New Zealand (384 in 2017). Unlike previous recent surveys, the percentage of PM replacements compared to total sales in both Australia and New Zealand rose. Pulse generator types implanted were predominantly dual chamber; Australia 77% (73% in 2017) and New Zealand 70% (68% in 2017). There were 1,509 biventricular PMs implanted in Australia (1,247 in 2017) and 172 in New Zealand (118 in 2017). Transvenous pacing leads were90% active fixation in the atrium and ventricle. There was an increase in ICD usage with Australia 4,519 new implants (4,212 in 2017) and New Zealand 449 (396 in 2017). New ICD implants per million population were 187 for Australia (175 in 2017) and 88 for New Zealand (90 in 2017). For the first time the survey included implantable event monitors with 6,933 being implanted in Australia. However, for proprietary reasons, survey figures for subcutaneous implantable defibrillators, leadless pacemakers and conduction system pacing have not been included. Both Australia and New Zealand have high PM and ICD implant numbers compared to the rest of the Asia Pacific region.

Background The diagnostic yield of post-mortem interrogation of cardiac implantable electronic devices (CIEDs) including pacemakers, defibrillators and implantable loop recorders has not been well described. Methods We reviewed all post-mortem CIED interrogations performed by our statewide Institute of Forensic Medicine between 2005–2020 for investigation of sudden or unexplained death. Results 260 patients (68.8% male, median age 72.8 years [IQR 62.7–82.2]) underwent post-mortem CIED interrogation (202 pacemakers, 56 defibrillators and 2 loop recorders). CIEDs were implanted for a median of 2.0 [IQR 0.75–5] years, with 19 devices requiring replacement (and 5 end of life). Post-mortem interrogation was successful in 256 (98.5%) cases. Potential CIED malfunction was identified in 21 (8.1%) cases: untreated ventricular arrhythmias (n=13), lead failures (n=3) and battery depletion (n=5). CIED interrogation directly informed cause of death in 130 (50.0%) cases, with fatal ventricular arrhythmias identified in 121 patients (46.5%). In retrospect, 72 (27.7%) patients had abnormalities recorded by their device in the 30 days preceding death: non-sustained ventricular tachycardia (n=26), rapid atrial fibrillation (n=17), longevity concerns (n=22), intrathoracic impedance alarms (n=3), lead issues (n=3) or therapy delivered (n=1). In 6 cases where the patient was found deceased after a prolonged time, CIED interrogation accurately determined time of death. In one case, CIED interrogation was the primary method of patient identification. Conclusion Post-mortem CIED interrogation frequently contributes important information regarding critical device malfunction, pre-mortem abnormalities, cause and time of death or patient identity. Device interrogation should be considered for select patients with CIEDs undergoing autopsy. Funding Acknowledgement Type of funding sources: None.

Atrial ectopics, also known as a premature atrial complexes (PAC) or atrial premature depolarisations (APD), are supraventricular beats arising from a focus other than the sinus node. Because the various foci provide an array of electrocardiographic (ECG) appearances, an extensive, but confusing nomenclature has developed. Atrial ectopics are a very common finding on Holter ECG monitoring at all ages, the incidence increasing in frequency with age. In the otherwise normal heart, they are generally infrequent and an innocent finding, but in patients with heart disease, they may be a harbinger to more serious atrial tachyarrhythmias. In this review, the ECG footprints of atrial ectopy will be defined. These footprints include prematurity and P wave morphology. The associated features of variable atrioventricular (AV) conduction, variable post-ectopic pauses and variable QRS morphology due to aberrancy will also be discussed. Each of these features will be explained in detail with ECG examples.

Modern cardiac pacing systems have sophisticated software to document, evaluate and record intrinsic and paced rhythms as well as correct pacing abnormalities and rhythm disturbances by applying algorithms, which are generally company specific. To the cardiologist and technologist, these algorithms may be difficult to interpret on both the 12-lead electrocardiograph (ECG) and Holter ambulatory monitoring recordings, which are usually performed because of patient symptoms or physician concern. The tracings may appear bewildering and mimic pacemaker malfunction, thus leading to unnecessary tests or even surgery. This review will define the common programmed pacemaker modes and describe a range of ECG appearances of normal pacemaker function during the application of testing, correcting or therapy algorithms.

The 12-lead resting electrocardiograph (ECG) of a patient with an implanted cardiac pacemaker is a snapshot of cardiac electrical activity at the time of recording and may provide valuable information on both pacemaker function and malfunction, as well as identifying the position of pacing leads in the heart. The traditional site for atrial pacing is within or adjacent to the right atrial appendage and paced P waves on the ECG have a normal frontal plane axis, whereas the traditional site for ventricular pacing is at the right ventricular apex with the ECG demonstrating a left bundle branch block configuration and a left axis. More recently, ventricular leads and to a lesser extent, atrial leads have been positioned in alternate non-traditional sites resulting in 12-lead ECG appearances which have characteristic features, that are generally poorly recognised. Left ventricular pacing results in a right bundle branch block configuration and an axis dependent on the position of the lead in the ventricle. This review will describe the ECG patterns of pacing lead positions in the right atrium and ventricle as well as positions in the left ventricle, whether intentional or unintentional.

With the recognised physiologic value of dual chamber pacing, there was, at the commencement of the 1980s, an intense search for sensors to enable ventricular pacemakers to alter the pulse repetition rate in response to physiologic demand. Manufacturers fell into two main groups; those who chose highly physiologic sensors often requiring special pacing leads and those whose sensors allowed a standard pacing lead. Thirteen (13) sensors for rate adaptive pacing progressed at least to human investigational studies. Eventually the activity sensor, which responded quickly to exercise, but not to emotional stimuli or pyrexia and used a standard lead would predominate, with all manufacturers eventually accepting what was the least physiologic sensor investigated. The activity-based rate response was not dependent on cardiac or pulmonary disease, which could nullify the response with many of the other sensors. Three (3) other sensors survived that period and are still available today; minute ventilation, closed loop stimulation and central venous temperature, with the first two incorporated with activity as dual sensor systems. This review will outline the development of all the sensors used for rate adaptive pacing.

Programmability is a stable, reversible change in the operating parameters of a cardiac implantable electronic device. The era of non-invasive programming began in 1972, with the development of a dedicated hand-held battery-operated device. Prior to this, there had been crude attempts, involving invasive procedures or a magnet, to change the pacemaker operating parameters. A non-invasive programming system requires an implanted pulse generator and an external programmer, communicating via an energy link. This was initially a pulsed magnetic field allowing opening and closing of a reed switch in the pulse generator in synchrony with the pulses. Soon after, radiofrequency communication was introduced and involved transmission of pulsing on-off radiofrequency bursts, which allowed complex encoding, that recognised the implanted hardware, prevented mis-programming, had security features and confirmed successful programming. As programming became more complex and sophisticated, programmers evolved into desktop models with programming wands and printers. By 1978, multiprogrammable programmers with bidirectional telemetry were introduced and became a driving force in the development of new cardiac implantable technologies and devices.

In 1963, soon after the first ventricular pacemakers were implanted at the Royal Melbourne Hospital, attempts were made to identify impending pacing failure, thus preventing sudden death in these very vulnerable patients. By 1970, patient numbers had increased, a formal regular pacemaker clinic was established, and guidelines and protocols developed. The clinic was staffed by a physician, a biomedical engineer and cardiac technicians. The unipolar, asynchronous, non-programmable pulse generators were powered by mercuric oxide/zinc batteries and implanted in the abdomen, using either transvenous or epimyocardial leads. Although, pulse generators were electively replaced at 3 years, most had already been replaced because of power source depletion, electronic failure or lead issues. Testing in all patients involved an electrocardiographic rhythm strip and electronic analysis of the stimulus artefact using a calibrated high-speed storage oscilloscope. Results were compared to previous studies and significant changes were interpreted as impending power source depletion. As a result of this testing, 97% of cases of impending power source depletion were detected prior to failure. These findings allowed testing each 4 months and for pulse generator life to be extended beyond three years. With ventricular triggered pulse generators, new testing procedures were designed. With time, visiting regional centres and clinical evaluation of new products became important functions of the clinic.

Cardiac pacing from the apex of the right ventricle has been shown to result in left ventricular dysfunction, atrial fibrillation, and increased mortality. To counter these effects, one of the strategies developed is avoidance of ventricular pacing when not necessary, using programmable algorithms to minimize ventricular pacing. Seven algorithms are available from 5 manufacturers. Four of the manufacturers have mode conversion algorithms that pace AAI(R) but, in the presence of failed atrioventricular (AV) conduction, demonstrate algorithm-offset and convert to DDD(R) with ventricular pacing. Three manufacturers do not have mode conversion but rather AV extension to encourage AV conduction. Each of these algorithms has a unique design and, when ventricular pacing is present, will regularly schedule conduction testing to encourage AV conduction and hence algorithm-onset. All of these algorithms seem to violate the rule of AV conduction by allowing the AV delay for sensed ventricular events to be longer than for ventricular paced events. The result is frequently bizarre electrocardiographic (ECG) appearances that often are unique to the company's algorithm but also suggest pacemaker malfunction. This review highlights and illustrates the features of these algorithms as they appear on ECG, and discusses other situations that result in unintended ventricular pacing.

In 1899, Karel Frederik Wenckebach described a cardiac arrhythmia with periodic dropped beats now referred to as a Wenckebach sequence. This was later shown to be due to a block in the atrioventricular node, but today, we identify Wenckebach sequences throughout the heart with most being recognised on the surface electrocardiograph as characteristic footprints. This manuscript will revisit Wenckebach atrioventricular block, the typical features of which only occur in about 15% of cases, with the remainder atypical. Earlier reports regarded Wenckebach atrioventricular sequences as rare as they are only occasionally seen on the surface 12-lead electrocardiograph. Today, however, with the increased use of ambulatory Holter monitoring, Wenckebach atrioventricular sequences occur in 4-6% of all traces and are particularly common at night in the young. Most, but not all cases are benign and the clinical spectrum will be reviewed. Atypical Wenckebach atrioventricular sequences are a complex group which will be analysed in detail with a broad range of illustrations. Outside the atrioventricular conducting system, such as in the sinus node, Wenckebach sequences may not be obvious as they are partially hidden from the electrocardiographic tracing. However, by understanding the sequence footprints, clues are available in interpreting tracing with periodic pauses. Dual chamber paced rhythms may show Wenckebach sequences due to electronic control of the atrioventricular delay. Rarely exit blocks at the cellular level in the atrium, ventricle or at the pacing electrode-tissue interface can demonstrate Wenckebach sequences recognised on the surface electrocardiograph.

Since its introduction as a clinical investigative tool, the 12-lead electrocardiograph (ECG) has been the gold standard for recognition of cardiac arrhythmias. The resting 12-lead ECG, however, gives only a rhythm snapshot in time, whereas arrhythmias maybe short-lived, paroxysmal and even asymptomatic making documentation in many patients very difficult. To overcome this, ambulatory ECG monitoring has been developed as a means of recording the ECG in patients over a set period of time, whether it be short-, medium- or long-term. With the miniaturisation of recording devices and advances in solid state technology, there has been a recent revolution in hardware design, so that the boundaries between these time-dependent devices have become blurred. Not surprisingly, the indications for monitoring have broadened as the quality and range of monitoring devices have become available. In this review, the indications for ambulatory ECG monitoring with emphasis on non-arrhythmic indications such as ST segment analysis, heart rate variability, signal averaged ECGs, diurnal QT and QTc analysis, obstructive sleep apnoea and vectorcardiography will be discussed. Also, the types of electrode systems used, lead placement, monitoring hardware, data collection, analysis and presentation as well as cost effectiveness of the investigation will be covered.

The transvenous implantation of cardiac devices may sometimes cause serious complications involving the coronary arteries. The left anterior descending artery may be injured during nonapical right ventricular implantation while a right atrial lead may injure the right or circumflex coronary artery. Injury of a left internal mammary graft to a coronary artery may cause myocardial infarction.

Background A cardiac implantable electronic device (CIED) survey was undertaken in Australia and New Zealand for calendar year 2017 and involved pacemakers (PMs) and implantable cardioverter-defibrillators (ICDs). Results and Conclusions For 2017, there were 17,971 (15,203 in 2013) new PMs sold in Australia and 1,811 (1,641 in 2013) implanted in New Zealand. The number of new PM implants per million population was 745 for Australia (652 in 2013) and 384 for New Zealand (367 in 2013). In both Australia and New Zealand, the number of PM replacements fell as a result of improved power source service life. Pulse generator types implanted were predominantly dual chamber; Australia 73% (74% in 2013) and New Zealand 68% (59% in 2013). There were 1,247 biventricular PMs implanted in Australia (661 in 2013) and 118 in New Zealand (83 in 2013). Transvenous pacing leads were overwhelmingly active fixation in both the atrium and ventricle. In Australia there was an increase in ICD usage with 4,212 new implants (3,904 in 2013), but a small fall in New Zealand to 396 (423 in 2013). The new ICD implants per million population were 175 for Australia (167 in 2013) and 90 for New Zealand (95 in 2013). There was a small reduction in biventricular ICDs in both Australia (2,195) and New Zealand (111).

Damage to the coronary arteries and related structures from pacemaker and implantable cardioverter-defibrillator lead implantation is a rarely reported complication that can lead to myocardial infarction and pericardial tamponade that may occur acutely or even years later. We summarize the reported cases of injury to coronary arteries and related structures and review the causes of troponin elevation in the setting of cardiac implantable electronic device implantation.

Although the first power source for an implantable pacemaker was a rechargeable nickel-cadmium battery, it was rapidly replaced by an unreliable short-life zinc-mercury cell. This sustained the small pacemaker industry until the early 1970s, when the lithium-iodine cell became the dominant power source for low voltage, microampere current, single- and dual-chamber pacemakers. By the early 2000s, a number of significant advances were occurring with pacemaker technology which necessitated that the power source should now provide milliampere current for data logging, telemetric communication, and programming, as well as powering more complicated pacing devices such as biventricular pacemakers, treatment or prevention of atrial tachyarrhythmias, and the integration of innovative physiologic sensors. Because the current delivery of the lithium-iodine battery was inadequate for these functions, other lithium anode chemistries that can provide medium power were introduced. These include lithium-carbon monofluoride, lithium-manganese dioxide, and lithium-silver vanadium oxide/carbon mono-fluoride hybrids. In the early 1980s, the first implantable defibrillators for high voltage therapy used a lithium-vanadium pentoxide battery. With the introduction of the implantable cardioverter defibrillator, the reliable lithium-silver vanadium oxide became the power source. More recently, because of the demands of biventricular pacing, data logging, and telemetry, lithium-manganese dioxide and the hybrid lithium-silver vanadium oxide/carbon mono-fluoride laminate have also been used. Today all cardiac implantable electronic devices are powered by lithium anode batteries.

Introduction Direct His bundle capture may negate ventricular electrical dyssynchrony induced by right ventricular (RV) apical pacing. We sought to evaluate if direct His bundle pacing is possible with conventional pacemaker lead implantation at various sites in the RV. Methods Consecutive patients underwent RV pacing using standard implantable active fixation pacing leads in a random order in the RV outflow tract, middle RV, and RV apex at stimulation threshold and at increasing voltages of 2.5, 5, 7.5, and 10 volts (V). At each location, QRS width and morphology on 12-lead electrocardiograph (ECG) were compared in sinus and paced rhythm at the different voltages. Results Twelve patients underwent a total of 2,160 paced QRS measurements. Progressive increases in stimulation voltage did not change QRS morphology or duration regardless of site of pacing (RV outflow tract, middle RV, and RV apex) in any of the 12 ECG leads. In addition, apart from the stimulation threshold between the RV outflow tract and RV apex, there was no statistically significant difference in QRS duration between the three pacing sites. Conclusion In patients with a baseline normal QRS duration, none of the three conventional RV pacing sites were able to produce QRS narrowing and capture the His-Purkinje system. Furthermore, based on paced QRS duration as an indirect surrogate of electrical LV dyssynchrony, there was no clear advantage of one pacing site over another.

Introduction There have been rare case reports of damage to adjacent coronary arteries by screw-in pacemaker and implantable cardioverter-defibrillator (ICD) leads. Our aim was to assess the proximity of pacemaker and ICD leads to the major coronary anatomy using cardiac computed tomography (CT). Methods Cardiac CT images were retrospectively analyzed to assess the spatial relationship of device lead tips to the major coronary anatomy. Results Fifty-two right ventricular (RV) leads (17 apical, 35 nonapical) and 35 right atrial (RA) leads were assessed. Leads on the RV antero-septal junction (20 of 52) were close (median 4.7 mm) to, and orientated toward, the left anterior descending (LAD) coronary artery. RA leads in the anterior (26 of 35) and lateral (seven of 35) walls of the RA appendage were not close to (16.9 ± 7.7 mm and 18.9 ± 12.4 mm, respectively) and directed away from the right coronary artery. However, an RA lead adjacent to the superior border of the tricuspid valve was 4.3 mm from the right coronary artery and an RA lead on the medial wall of the RA appendage was 1.6 mm away from the aorta. An RV pacemaker lead in the lateral wall of the RV inlet was 3.4 mm from the right coronary artery. Conclusions In our cohort, a majority of RV leads were on the antero-septal junction and close to the overlying LAD coronary artery. RA leads adjacent to the tricuspid valve or on the medial RA appendage were in close proximity to the right coronary artery and aorta, respectively.

Introduction We aimed to assess the utility of cardiac computed tomography (CT) in the evaluation of right atrial (RA) and right ventricular (RV) pacemaker and implantable cardiac defibrillator lead perforation. Methods Images from a 320-slice electrocardiogram-gated cardiac CT scanner were retrospectively independently analyzed by two reviewers for lead position, pericardial effusion, and perforation. Perforation results were correlated with pacing sensing, impedance, and threshold measurements. Results A total of 52 patients had RV leads and 35 had RA leads. Five of 17 RV apical, one of 35 RV nonapical, and none of the 35 RA leads perforated through the myocardium on CT imaging criteria. Two “clinically” perforated leads (that had protruded 5 mm and 15 mm from the outer edge of the myocardium) had pericardial effusions and changes in pacing parameters, and required RV lead repositioning. In contrast, there were four apparent “radiologic” perforations (that had protruded only an average 1.5 ± 0.5 mm from the outer edge of the myocardium) that did not require repositioning. These had the radiologic appearance of perforation on cardiac CT; however, they were not associated with pericardial effusions or significant changes in RV pacing lead sensing, impedance, and threshold measurements. Conclusions Cardiac CT scanning with multiplanar reformatting is useful for documenting lead position and assessing for possible cardiac perforation. The clinical significance and natural history of leads with only the appearance of perforation on cardiac CT is uncertain.

Introduction It is hypothesized that pacing the right ventricular (RV) septum is associated with less deleterious outcomes than RV apical pacing. Our aim was to validate fluoroscopic and electrocardiography (ECG) criteria for describing pacemaker and implantable cardioverter defibrillator RV “septal” lead position against the proposed gold standard: cardiac computed tomography (CT). Methods Using the conventional fluoroscopic criteria, we intended to place RV nonapical leads on the interventricular septum. Lead positions were later retrospectively analyzed with CT and correlated with ECGs and fluoroscopic projections: posterior-anterior, 40° left anterior oblique (LAO), 40° right anterior oblique (RAO), and left lateral. Results Only 21% (nine of 35) of presumed “septal” RV nonapical leads using the conventional fluoroscopic criteria were on the true septum. A schema developed to define septal position in the RAO fluoroscopic view had high agreement with CT images. ECG criteria had only fair to moderate agreement with CT. The paced QRS duration was significantly longer (P < 0.001) with RV apical pacing (176 ± 10.7 ms), compared to RV nonapical pacing (144.5 ± 14.3 ms). Conclusion Using the conventional fluoroscopic criteria, only a minority of RV leads were implanted on the true RV septum. Instead, aiming for the middle of the cardiac silhouette in the RAO fluoroscopic view, confirming rightward orientation in the LAO view, and having a paced QRS duration

Cardiac implantable electronic devices (CIEDs) play a vital role in the management of cardiac rhythm disturbances. The devices are comprised of two primary components: a generator and lead joined by a connector. Original pacemaker lead connectors were created de novo at the time of implantation or replacement and were very unreliable. With the development of new lead designs, creation of a standard connector configuration, the IS-1 connector became mandatory. Similar connector development also occurred with the advent of the implantable cardioverter defibrillator (ICD), resulting in creation of the high voltage standard: the DF-1 connector. Differing from a pacemaker lead, the ICD lead connector requires one IS-1 connector and one or two DF-1 connectors, resulting in a large cumbersome lead connector and generator header block. Recently, a revolutionary quad pole single plug connector standard has been approved for market release. These are the single-pin DF4 and IS4 lead connectors that carry low- and high-voltage poles or all low-voltage poles, respectively. These connectors, together with new labeling guidelines, have simplified operative procedures and reduced errors, when mating lead connectors into the generator's connector block.

Transvenous pacing has revolutionized the management of patients with potentially life-threatening bradycardias and at its most basic level ensures rate support to maintain cardiac output. However, we have known for at least a decade that pacing from the right ventricle (RV) apex can induce left ventricle (LV) dysfunction, atrial fibrillation, heart failure, and maybe an increased mortality. Although pacemaker manufacturers have developed successful pacing algorithms designed to minimize unnecessary ventricular pacing, it cannot be avoided in a substantial proportion of pacemaker-dependent patients. Just as there is undoubted evidence that RV apical pacing is injurious, there is emerging evidence that pacing from the RV septum is associated with a shorter duration of activation, improved haemodynamics, and less LV remodelling. The move from traditional RV apical pacing to RV septal pacing requires a change in mindset for many practitioners. The anatomical landmarks and electrocardiograph features of RV septal pacing are well described and easily recognized. While active fixation is required to place the lead on the septum, shaped stylets are now available to assist the implanter. In addition, concerns about the stability and longevity of steroid-eluting active fixation leads have proven to be unfounded. We therefore encourage all implanters to adopt RV septal pacing to minimize the potential of harm to their patients.

A worldwide cardiac pacing and implantable cardioverter-defibrillator (ICD) survey was undertaken for calendar year 2009 and compared to a similar survey conducted in 2005. There were contributions from 61 countries: 25 from Europe, 20 from the Asia Pacific region, seven from the Middle East and Africa, and nine from the Americas. The 2009 survey involved 1,002,664 pacemakers, with 737,840 new implants and 264,824 replacements. The United States of America (USA) had the largest number of cardiac pacemaker implants (225,567) and Germany the highest new implants per million population (927). Virtually all countries showed increases in implant numbers over the 4 years between surveys. High-degree atrioventricular block and sick sinus syndrome remain the major indications for implantation of a cardiac pacemaker. There remains a high percentage of VVI(R) pacing in the developing countries, although compared to the 2005 survey, virtually all countries had increased the percentage of DDDR implants. Pacing leads were predominantly transvenous, bipolar, and active fixation. The survey also involved 328,027 ICDs, with 222,407 new implants and 105,620 replacements. Virtually all countries surveyed showed a significant rise in the use of ICDs with the largest implanter being the USA (133,262) with 434 new implants per million population. This was the largest pacing and ICD survey ever performed, because of mainly a group of loyal enthusiastic survey coordinators. It encompasses more than 80% of all the pacemakers and ICDs implanted worldwide during 2009.

Background: Prolonged right ventricular (RV) apical pacing produces dysynchronous ventricular contraction, which may result in left ventricular (LV) dysfunction, whereas septal pacing sites might reflect a more synchronous LV activation. This study examined a method of evaluating alternate RV pacing sites using a template scoring system based on measuring the angle of lead attachment in the 40o left anterior oblique (LAO) fluoroscopic view and its effect on altering the loop of lead in the RV. Methods: Twenty-three consecutive patients for RV pacing were enrolled. Conventional active fixation leads were positioned in either the RV outflow tract (RVOT) or mid RV using a stylet designed for septal placement (Model 4140, St. Jude Medical, St. Paul, MN, USA). Using LAO cine fluoroscopy, a generous loop of lead was inserted into the RV chamber and the change in angle of attachment determined. Results: Successful positioning of pacing leads at the RVOT septum (18 patients) and mid-RV septum (five patients) was achieved. With introduction of more lead into the RV chamber, the angle of attachment in the LAO projection altered over a range of 6o–32o for all patients with a mean of 14.6 ± 6.6o. In 87% of patients, the range was predominantly within the same template score with only minor overlap into another zone. Conclusions: This study shows that the angle of lead attachment in the RV is altered by introducing more lead, but in most cases, the template score remains the same. Further studies are required to determine the accuracy and efficacy of the templates. (PACE 2011; 34:1080–1086)

Background: Prolonged right ventricle (RV) apical pacing is associated with left ventricle (LV) dysfunction due to dysynchronous ventricular activation and contraction. Alternative RV pacing sites with a narrower QRS compared to RV pacing might reflect a more physiological and synchronous LV activation. The purpose of this study was to compare the QRS morphology, duration, and suitability of RV outflow tract (RVOT) septal and mid-RV septal pacing. Methods: Seventeen consecutive patients with indication for dual-chamber pacing were enrolled in the study. Two standard 58-cm active fixation leads were passed to the RV and positioned in the RVOT septum and mid-RV septum using a commercially available septal stylet (model 4140, St. Jude Medical, St. Paul, MN, USA). QRS duration, morphology, and pacing parameters were compared at the two sites. The RV lead with less-satisfactory electrical parameters was withdrawn and deployed in the right atrium. Results: Successful positioning of the pacing leads at the RVOT septum and mid-RV septum was achieved in 15 patients (88.2%). There were no significant differences in the mean stimulation threshold, R-wave sensing, and lead impedance between the two sites. The QRS duration in the RVOT septum was 151 ± 14 ms and in the mid-RV septum 145 ± 13 ms (P = 0.150). Conclusions: This prospective observational study shows that septal pacing can be reliably achieved both in the RVOT and mid-RV with active fixation leads using a specifically shaped stylet. There are no preferences in regard to acute lead performance or paced QRS duration with either position. (PACE 2010; 33:1169–1173)

Prolonged right ventricular (RV) apical pacing is associated with progressive left ventricular dysfunction due to dysynchronous ventricular activation and contraction. RV septal pacing allows a narrower QRS compared to RV apical pacing, which might reflect a more physiological and synchronous ventricular activation. Previous clinical studies, which did not consistently achieve RV septal pacing, were not confirmatory and need to be repeated. This review summarizes the anatomy of the RV septum, the radiographic appearances of pacing leads in the RV, the electrocardiograph correlates of RV septal lead positioning, and the techniques and tools required for implantation of an active-fixation lead onto the RV septum. Using the described techniques and tools, conventional active-fixation leads can now be reliably secured to either the RV outflow tract septum or mid-RV septum with very low complication rates and good long-term performance. Even though physiologic and hemodynamic studies on true RV septal pacing have not been completed, the detrimental effects of long-term RV apical pacing are significant enough to suggest that it is now time to leave the RV apex and secure all RV leads onto the septum.

A pacemaker (PM) and implantable cardioverter-defibrillator (ICD) survey was undertaken in Australia (Au) and New Zealand (NZ) for 2005.Compared to the 2001 survey, significant increases in implantation numbers were recorded. For 2005, the total new PMs implanted was 11,850 in Au (9498 in 2001) and 1134 in NZ (914 in 2001). The number of new PM implants per million population was 590 in Au (486 in 2001) and 275 in NZ (245 in 2001). Biventricular PMs were documented for the first time with 461 implants in Au and 16 in NZ. Pulse generator types were predominantly dual chamber with 73% in Au (70% in 2001) and 51% in NZ (54% in 2001). Pacing leads were overwhelmingly transvenous and bipolar with an increase in the use of active fixation leads in preference to tined leads. There was a marked increase in the use of ICDs with 2864 new implants in Au (956 in 2001) and 134 in NZ (86 in 2001). The new ICD implants per million population were 142 in Au (49 in 2001) and 33 in NZ (23 in 2001). ICDs were 35% biventricular in Au and 10% in NZ. The Au Northern Territory is included for the first time.

BACKGROUND: There is marked heterogeneity in right ventricular outflow tract (RVOT) pacemaker lead placement using conventional leads. As a result, we have sought to identify a reproducible way of placing a ventricular lead onto the RVOT septum. METHODS AND RESULTS: A major determinant is the shape of the stylet used to deliver the active-fixation lead. We compared stylet shapes and configurations in patients who initially had a ventricular lead placed onto the anterior or free wall of the RVOT and then had the lead repositioned onto the septum. All leads were loaded with a stylet fashioned with a distal primary curve to facilitate delivery of the lead to the pulmonary artery, then using a pullback technique the lead was retracted to the RVOT. All lead placements were confirmed by fluoroscopy and electrocardiography. Anterior or free wall placement was achieved by the stylet having either the standard curve or an added distal anterior angulation. In contrast, septal lead positioning was uniformly achieved by a distal posterior angulation of the curved stylet. This difference in tip shape was highly predictive for septal placement (P < 0.001). With septal pacing, a narrower QRS duration was noted, compared to anterior or free wall pacing (136 vs 155 ms, P < 0.001). All pacing parameters were within acceptable limits. CONCLUSION: Using appropriately shaped stylets, pacing leads can now be placed into specific positions within the RVOT and in particular septal pacing can be reliably and reproducibly achieved. This is an important step in the standardization of lead placement in the RVOT.

Background Malposition of electrocardiograph (ECG) leads is poorly recognised even by cardiologists who report tracings. When ECG tracings are regularly performed by doctors, nurses or technicians, lead malposition is very uncommon particularly if the operator can also interpret the findings. However, a significant proportion of 12-lead ECG tracings are today performed in a doctor's surgery or by private pathology services, often in haste without sufficient attention to correct lead positioning. As a result, a variety of malposition combinations occur, which in turn may confuse the interpreter of the ECG tracing, leading to incorrect diagnoses. Objectives To investigate various combinations of ECG lead malposition and determine if characteristic findings can be summarised into identifiable footprints. Methods In 10 normal subjects, 12-lead ECGs were performed with normal lead positioning as well as six limb lead malpositions and reversal of chest leads. Results In all subjects, there was consistency in the ECGs performed allowing the creation of five characteristic and easily identifiable footprints. Conclusions A summary of the footprints of ECG lead malposition should be readily available for those who perform ECGs, those who interpret the tracings and those responsible for clinical care.

An international questionnaire survey was carried out in Asia Pacific, Europe, Latin America and North America to assess the impact of reimbursement on the indications, types of device prescription and waiting time for pacemakers, implantable cardioverter defibrillators (ICD) and radiofrequency ablation therapy for cardiac arrhythmias. The indications for cardiac pacing can be restricted to more symptomatic patients when funding is limited, and new therapy such as cardiac resynchronization therapy (CRT) is restricted in many regions. ICD usage may be limited to secondary prevention candidates because of reimbursement, but referral doctor's ambivalence and knowledge are also important issues independent of the types of health care system. Radiofrequency ablation is generally well accepted, but reimbursement is heterogeneous, with non-fluoroscopic mapping being reimbursed only in a limited way worldwide. Thus with the exception of a well-developed health care system, reimbursement has a major impact on the delivery of arrhythmia management devices and procedures worldwide.

OBJECTIVE To characterize the pacing site in an unselected series of patients undergoing right ventricular outflow tract (RVOT) lead placement and investigate the role of the electrocardiogram (ECG) in predicting implantation. BACKGROUND Right ventricular apical pacing is associated with long-term adverse effects on left ventricular function, fuelling interest in alternative pacing sites, especially the RVOT. Previous studies have been conflicting, possibly due to poor definition of pacing site within the RVOT. METHODS In 150 patients undergoing pacemaker implantation, implanters were asked to place the lead in the RVOT. Radiographs were performed in the antero-posterior (AP) and 40 degrees right and left anterior-oblique projections post procedure. Fifty-six had left lateral radiographs. Lead position was categorized using AP/RAO (right anterior oblique) to confirm RVOT placement and left anterior oblique to distinguish free wall from septum. A 12-lead ECG was performed during ventricular pacing. RESULTS Leads were below the RVOT in 18. Of the remaining 132, the majority (94%) were in the inferior/low RVOT. Eighty-one out of 132 were septal and 51 free wall. Septal sites were associated with shorter QRS duration (134 ms vs 143 ms, P < 0.02). Free wall sites displayed more frequent notching of the inferior leads (P < 0.01). A negative deflection in lead I provided a positive predictive value of 90% for septal sites. In those with lateral radiographs, a posteriorly projected lead was 100% specific for septal placement. CONCLUSIONS This study demonstrates the heterogeneity of lead placement within the RVOT. Septal and free wall sites display characteristic ECG patterns which may be used to aid placement. The left lateral radiograph is useful in confirming a true septal location.

Despite the increasingly widespread use of active-fixation leads, long-term clinical follow-up of pacing lead outcomes is lacking. The aim was to analyze pacing parameters over a 2-year follow-up. We performed a prospective observational study of consecutive new pacemaker implants using the 1488T St. Jude (100) and the Medtronic 5076 (100) active-fixation leads. Detailed analysis of pacing parameters was collected at implant, day 1, and 1, 3, 6, 12, 18, and 24 months.One hundred patients underwent implantation of 100 dual-chamber pacemakers. Initial pacing parameters in the ventricle were threshold 0.7 +/- 0.2 V, R wave 12.0 +/- 6.5 mV, and impedance 879 +/- 224 Omega. Threshold increased significantly from day 1 (0.7 +/- 0.2 V) to month 1 (0.9 +/- 0.6 V, P0.01) and remained stable over the long term. Four of the 100 patients had a threshold2 V (mean 3.3 +/- 0.9 V) all between day 1 and month 3. For all patients, R wave remained stable, but impedance declined significantly from day 1 (879 +/- 184 Omega) to month 1 (677 +/- 122 Omega, P0.01). There were no ventricular lead complications. Initial pacing parameters in the atrium were threshold 0.9 +/- 0.3 V, P wave 3.3 +/- 2.4 mV, and impedance 606 +/- 144 Omega. Threshold remained stable over the long-term follow-up. One of 100 patients had a rise in threshold2 V (2.2 V) between day 1 and month 1. No patients underwent lead repositioning. Sensing and impedance remained stable over the long term. Patient follow-up was completed in 94% (6 unrelated deaths). There was an 8% incidence of atrial fibrillation.Active-fixation leads are generally associated with stable long-term pacing parameters.

Background The aim of this study was to characterize acute and medium-term pacemaker lead performance with the two most commonly used glucocorticosteroids: dexamethasone sodium phosphate and dexamethasone acetate. Methods Forty sets of atrial and ventricular passive-fixation leads containing either dexamethasone sodium phosphate or dexamethasone acetate were implanted as dual chamber pacemakers. Randomization was equally distributed to both arms of the study. Stimulation thresholds, lead impedance, and sensing were measured on the day of implant, day 1, 1 month, 3 months, and 6 months following the implant. Results For the dexamethasone sodium phosphate arm, the atrial stimulation thresholds were 0.9 +/- 0.1 V at implant and 0.8 +/- 0.1 V at 6 months, and in the ventricle 0.5 +/- 0.1 V at implant and 0.6 +/- 0.1 V at 6 months. In the dexamethasone acetate arm, the atrial stimulation thresholds were 0.7 +/- 0.1 V at implant and at 6 months, and in the ventricle 0.5 +/- 0.1 V at implant and at 6 months. There were no significant differences between dexamethasone sodium phosphate or dexamethasone acetate leads for stimulation thresholds at any of the intervals of follow-up. P- and R-wave sensing were similarly maintained over the duration of follow-up with no significant differences between groups at any of the intervals of follow-up. Pacing lead impedance showed a trend towards lower values in the dexamethasone acetate arm, which only reached statistical significance at 3 months and beyond for ventricular leads. Conclusions Leads containing dexamethasone sodium phosphate and dexamethasone acetate demonstrate equivalent and excellent acute and medium-term pacemaker lead performance characteristics.

Selective site right ventricular pacing has been suggested as an approach to reduce the incidence of ventricular dysfunction and hopefully influence the morbidity resulting from traditional right ventricular apical pacing. Pacing from the right ventricular apex allows a stable ventricular rate, and together with atrial pacing and sensing, helps maintain atrioventricular synchrony but does not allow physiological activation of the left ventricle. Traditional atrial pacing sites like the right atrial appendage may encourage atrial tachyarrhythmias, whereas lead placement in right atrial septal sites may reduce the frequency of symptomatic atrial tachyarrhythmia episodes, especially when combined with prevention algorithms. Researchers attempting to pace the heart from these selective sites have been hindered by the lack of uniform definitions of where these sites actually lie and the inadequacy of tools to consistently reach these locations and verify correct placement. This lack of definition consensus may have contributed to the apparent conflict of data, particularly in the right ventricle. There is an urgent need for a standardization of terms and identifying measures for selective pacing sites.

A pacemaker (PM) and implantable cardioverter-defibrillator (ICD) survey was undertaken in Australia (Au) and New Zealand (NZ) for calendar year 2001.Compared to the 1997 survey, significant increases in implantation numbers were recorded. For 2001, the total new PMs implanted was 9498 Au (6405 in 1997) and 914 NZ (823 in 1997). The number of new PM implants per million population was 486 Au (345 in 1997) and 245 NZ (228 in 1997). There were also significant increases in PM replacements between surveys with 1536 in Au (735 in 1997) and 195 in NZ (126 in 1997). Dual chamber implants were 71% Au (65% in 1997) and 56% NZ (55% in 1997). Pacing leads were overwhelmingly transvenous and bipolar with an increase in the use of active fixation leads in preference to tined leads, particularly in the atrium. There was a marked increase in the use of ICDs. The implants were 956 Au (449 in 1997) and 86 NZ (31 in 1997) with new implants per million population being 49 Au and 23 NZ. A breakdown of data for the six Au States and well as comparisons of similar surveys from other countries is presented.

On occasion, patients with a tricuspid annuloplasty ring may require permanent cardiac pacing. Although it is technically possible to pass a ventricular transvenous lead through a tricuspid valve with an annuloplasty ring, the procedure is complicated by considerable chamber enlargement and mechanical distortion of the tricuspid valve often with severe residual tricuspid regurgitation. Over a 25-month period, transvenous ventricular lead placement following insertion of a tricuspid annuloplasty ring was successfully performed in five patients (three women). The patient mean age was 66 years (range 55-77 years). Four cases had slow atrial fibrillation and another paroxysmal atrial fibrillation requiring His-bundle ablation. Two patients had mitral valve replacement and two aortic and mitral valve replacements. All patients had residual severe to torrential tricuspid regurgitation. Seven ventricular steroid-eluting screw-in leads were used. Single leads were used in three cases, whereas in two others, two ventricular leads were attached to a dual chamber pulse generator. Although technically difficult, ventricular lead placement was successful using standard guidewires with broad curvatures. Satisfactory acute and follow-up stimulation thresholds and sensing were obtained with the only complication being an intraoperative lead dislodgement, prompting a second ventricular lead. Successful transvenous lead placement across a tricuspid annuloplasty ring is possible.

A pacemaker (PM) and implantable cardioverter-defibrillator (ICD) survey was undertaken in Australia and New Zealand for calendar year 2013.For 2013, PMs sold as new implants in Australia was 15,203 (12,523 in 2009) and implanted in New Zealand were 1,641 (1,277 in 2009). The number of new PM implants per million population 652 for Australia (565 were in 2009) and 367 for New Zealand (299 in 2009). Although PM replacements rose in New Zealand, there was a fall in Australia as a result of improved power source service life. Pulse generator types sold in Australia were predominantly dual chamber 74% (71% in 2009) and implanted in New Zealand 59% (54% in 2009). There were 661 biventricular PMs implanted in Australia (446 in 2009) and 83 in New Zealand (45 in 2009). Transvenous pacing leads were overwhelmingly bipolar with preferences for active fixation leads, although, since 2009, there has been a minor resurgence in Australia of passive fixation lead usage in the atrium from 20 to ∼24%. There was also a marked increase in the ICD implants with 3904 new implants in Australia (3555 in 2009) and 423 in New Zealand (329 in 2009). The new ICD implants per million population were 167 for Australia (160 in 2009) and 95 for New Zealand (77 in 2009). Biventricular ICD implants increased significantly in both Australia (2211) and New Zealand (118).

We aimed to assess the utility of cardiac computed tomography (CT) in the evaluation of right atrial (RA) and right ventricular (RV) pacemaker and implantable cardiac defibrillator lead perforation.Images from a 320-slice electrocardiogram-gated cardiac CT scanner were retrospectively independently analyzed by two reviewers for lead position, pericardial effusion, and perforation.Perforation results were correlated with pacing sensing, impedance, and threshold measurements.A total of 52 patients had RV leads and 35 had RA leads. Five of 17 RV apical, one of 35 RV nonapical, and none of the 35 RA leads perforated through the myocardium on CT imaging criteria. Two "clinically" perforated leads (that had protruded 5 mm and 15 mm from the outer edge of the myocardium)had pericardial effusions and changes in pacing parameters, and required RV lead repositioning. In contrast,there were four apparent "radiologic" perforations (that had protruded only an average 1.5±0.5 mm from the outer edge of the myocardium) that did not require repositioning. These had the radiologic appearance of perforation on cardiac CT; however, they were not associated with pericardial effusions or significant changes in RV pacing lead sensing, impedance, and threshold measurements.Cardiac CT scanning with multiplanar reformatting is useful for documenting lead position and assessing for possible cardiac perforation. The clinical significance and natural history of leads with only the appearance of perforation on cardiac CT is uncertain.

The electrode-tissue interface is that area lying between the cathode of a low-voltage implantable pacemaker or cardioverter-defibrillator (ICD) lead and the endocardium or epi-myocardium of the cardiac chamber being paced. The electrical stimulus that is delivered to this interface is responsible for myocyte depolarization with consequent cardiac contraction. The process by which this occurs is reasonably well understood and any explanation requires a basic understanding of the physics and cellular electrophysiology of pacing. The effective and efficient delivery of electrical energy to the myocardium via the lead is dependent on many factors to be discussed in this review. However, despite numerous evolutionary changes occurring in the cathode's material, design, and surface configuration, it was not until the incorporation of steroid-elution to the electrode-tissue interface that reliable and significantly low stimulation threshold cardiac pacing became possible.

Background Heartbeat International is a little-known 501(c)(3) charitable organization, which for the past 25 years has been responsible for the implantation and follow-up of cardiac implantable electronic devices in over 9000 indigent recipients in predominantly developing countries. Although the concept was founded in Guatemala over 30 years ago, it took the vision and drive of Dr. Henry D. McIntosh, M.D., M.A.C.C, to create Heartbeat International in 1984. Discussion The organization works through Pacemaker Banks established by local Rotary International chapters and other civic organizations in 24 countries over four continents and is dependent on the generosity of the implantable device manufacturers and teams of dedicated physicians and hospital personnel in the countries of operation. Since the vast majority of personnel are voluntary, 90 cents of every donated dollar directly supports the provision, implantation of devices, and follow-up care. Each US$500 provides a pacemaker to one needy patient. The organization's co-mission is also to educate and train implanting physicians in pacing and implantable cardioverter-defibrillator technology. The program remains dependent on the pacemaker manufacturers, who work in an environment of regulatory constraint and economic imperatives. With an ever growing demand for these devices, Heartbeat International will in the future need to increase its operating budget to purchase implantable inventory.

Background —Tachycardia-mediated mechanical remodeling of the atrium is considered central to the pathogenesis of thromboembolism associated with chronic atrial fibrillation. Whether atrial mechanical remodeling also occurs in response to atrial stretch induced by chronic asynchronous ventricular pacing in patients with permanent pacemakers is unknown. Methods and Results —The study design was a prospective randomized comparison between 21 patients paced chronically in the VVI mode and 11 patients paced chronically in the DDD mode for 3 months. Left atrial appendage (LAA) function and the presence of spontaneous echo contrast (SEC) were determined with transesophageal echocardiography (TEE) within 24 hours of pacemaker implantation and after 3 months. The VVI patients were then programmed to DDD and underwent a third TEE after DDD pacing for an additional 3 months. After chronic VVI pacing, LAA velocity decreased from 82.4±29.0 to 42.1±25.4 cm/s ( P P P P P Conclusions —Chronic loss of AV synchrony induced by VVI pacing is associated with mechanical remodeling of the left atrium, which may reverse after the reestablishment of AV synchrony with DDD pacing. This process may be partly responsible for the higher incidence of thromboembolism observed in patients undergoing VVI pacing compared with AV sequential pacing.